Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

@inproceedings{Cobble2012DifferentiatingAI,
  title={Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus},
  author={Michael E. Cobble},
  booktitle={Diabetology & Metabolic Syndrome},
  year={2012}
}
The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin system to regulate glucose homeostasis, there are important clinical differences among the five agents currently available in the U.S. For example, the GLP-1R agonists require subcutaneous administration, produce pharmacological levels of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

  • Clinical diabetes : a publication of the American Diabetes Association
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.

  • Therapeutic advances in endocrinology and metabolism
  • 2014
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 70 REFERENCES

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL